Is the MVP regimen less active than previously described? Results of a phase II study in advanced non-small cell lung cancer

被引:5
作者
Ferrigno, D
Buccheri, G
机构
[1] Department of Respiratory Medicine, A. Carle Hospital, Cuneo
[2] Dept. of Respiratory Medicine, A. Carle Hospital
关键词
D O I
10.3109/02841869609109918
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Combination chemotherapy with anti-proliferative agents is often used in patients with advanced non-small cell lung cancer (NSCLC) in good performance status, The mitomycin C, vinblastine and cisplatin (MVP) regimen has been the Eastern Cooperative Oncology Group (ECOG) standard for several years because of high response rates in spite of significant toxicity, In a phase II study, we observed 55 consecutive patients treated with MVP chemotherapy using the same dosage, schedule, and precautions as used by the ECOG group, The dose intensity reached for each drug was 85% of the projected dose, Fifty-one patients were assessable for response and toxicity, while all subjects were evaluable for survival, There was no complete remissions, 8 partial (15%), 34 stable (66%) and 9 progressive (17%) in patients, The median survival rate was 34 weeks (95% confidence interval 28-37 weeks), There were no treatment-related deaths and no grade 4 toxicity, Alopecia and emesis were the most significant adverse effects, Haematological toxicity was minimal. Other side-effects, such as neuropathy and nephrotoxicity, were also rare, Hence, response rates and toxic complications were lower than previously reported. We conclude that the MVP regimen has to be re-evaluated.
引用
收藏
页码:435 / 439
页数:5
相关论文
共 34 条
  • [11] DIXON WJ, 1988, BMDP STAT SOFTWARE, P57
  • [12] SYMPTOM RELIEF WITH MVP (MITOMYCIN-C, VINBLASTINE AND CISPLATIN) CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG-CANCER
    ELLIS, PA
    SMITH, IE
    HARDY, JR
    NICOLSON, MC
    TALBOT, DC
    ASHLEY, SE
    PRIEST, K
    [J]. BRITISH JOURNAL OF CANCER, 1995, 71 (02) : 366 - 370
  • [13] CHEMOTHERAPY FOR ADVANCED NON-SMALL-CELL LUNG-CANCER - HOW MUCH BENEFIT IS ENOUGH
    GRILLI, R
    OXMAN, AD
    JULIAN, JA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) : 1866 - 1872
  • [14] HARAF DJ, 1992, SEMIN ONCOL, V19, P72
  • [15] CHEMOTHERAPY AND SURVIVAL OF PATIENTS WITH NON-SMALL-CELL LUNG-CANCER - A CONTRARY VIEW
    HASKELL, CM
    [J]. CHEST, 1991, 99 (06) : 1325 - 1326
  • [16] IHDE DC, 1992, NEW ENGL J MED, V327, P1434
  • [17] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [18] Karnofsky D.A., 1949, EVALUATION CHEMOTHER, P199
  • [19] THE CALCULATION OF ACTUAL OR RECEIVED DOSE INTENSITY - A COMPARISON OF PUBLISHED METHODS
    LONGO, DL
    DUFFEY, PL
    DEVITA, VT
    WESLEY, MN
    HUBBARD, SM
    YOUNG, RC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (11) : 2042 - 2051
  • [20] MARINO P, 1993, LANCET, V342, P741